ImmunoPrecise Antibodies Ltd. has announced a significant advancement in the discovery of a universal dengue vaccine through its AI-driven platform, LENSai™, powered by HYFT® technology. The platform has identified a single target conserved across all dengue serotypes, paving the way for a universal vaccine design. This breakthrough could potentially extend beyond dengue, with plans to apply the technology to other infectious diseases such as HIV, Norovirus, and RSV, as well as explore applications in oncology. The end-to-end platform aims to reduce the time and cost of early-stage vaccine development by integrating deep learning and structural predictions with literature-mined knowledge, offering a new approach to tackling complex viral challenges.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.